A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

Petrylak, Daniel Peter; Vogelzang, Nicholas J.; Chatta, Gurkamal S.; Fleming, Mark T.; Smith, David C.; Appleman, Leonard Joseph; Hussain, Arif; Modiano, Manuel; Singh, Parminder; Tagawa, Scott T.; Gore, Ira; McClay, Edward Francis; Mega, Anthony E.; Sartor, A. Oliver; Somer, Bradley G.; Wadlow, Raymond Couric; Shore, Neal D.; Stambler, Nancy; DiPippo, Vincent A.; Israel, Robert Joseph

doi:10.1200/jco.2015.33.7_suppl.144

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

144 Background: PSMA is a validated target that is overexpressed selectively on prostate cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule disrupting agent MMAE which binds to PSMA-positive cells, inducing cytotoxicity. A phase 1 study showed activity and tolerab…